Trial Profile
Linagliptin and Mesenchymal Stem Cells: A Pilot Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- 05 Nov 2020 Status changed from recruiting to completed.
- 19 May 2016 The inclusion criteria has been expanded to include patients with minimum age of 18 years.
- 01 Dec 2015 Number of treatment arms changed from 1 to 2, Linagliptin control group was added to treatment arms. Hence, study design changed from single group assignment to parallel, patient number also changed from 8 to 18, according to ClinicalTrials.gov record.